TYK2 and rheumatoid arthritis: Given the selectivity profile of upadacitinib, potential pathogenic drivers in RA such as GM-SCF, IL-2, IL-9, IL-12, and IL-23, mediated by JAK2, JAK3, and TYK2 will be less impacted at efficacious concentrations.